Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.A Belgian Precision 2 study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518522-32-00

Acronym

BSMO 1-2018

Enrollment

351

Registered

2024-10-18

Start date

2019-02-07

Completion date

2025-10-31

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basket tumors

Brief summary

Response rate according to RECIST 1.1, Response duration

Detailed description

Correlate efficacy with locus-specific LOH in the tumors in case of cancers atypical for the germline mutations., PFS, OS, Safety by reporting all adverse events

Interventions

DRUGLynparza 100 mg film-coated tablets

DRUGLynparza 150 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Response rate according to RECIST 1.1, Response duration	—

Secondary

Measure	Time frame
Correlate efficacy with locus-specific LOH in the tumors in case of cancers atypical for the germline mutations., PFS, OS, Safety by reporting all adverse events	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026